Combined oral contraceptives: Benefits and risks
- Авторлар: Dubrovina S.O.1
-
Мекемелер:
- Scientific Research Institute of Obstetrics and Pediatrics of Rostov State Medical University
- Шығарылым: № 9 (2017)
- Беттер: 132-137
- Бөлім: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248053
- DOI: https://doi.org/10.18565/aig.2017.9.132-7
- ID: 248053
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Objective. To carry out a systematic analysis of the data available in the current literature on the benefits and possible risks of combined oral contraceptive (COC) use. Material and methods. The review included the data of foreign articles published in the past 10 years and found in PubMed on this topic. Results. This paper disproves the myths that exist about COCs and sets out their benefits and the rules of switching from COCs to hormone replacement therapy. It presents data on the effect of COCs on cancers at different sites. The possible risks of COCs are assessed. Conclusion. COCs are not only a reliable means of contraception, but also have a number of significant benefits, including for reducing the risk of cancers at different sites. To avoid possible side effects, all possible benefits and risks of COCs should be weighed before their prescription.
Негізгі сөздер
Толық мәтін
Авторлар туралы
Svetlana Dubrovina
Scientific Research Institute of Obstetrics and Pediatrics of Rostov State Medical University
Email: s.dubrovina@gmail.com
professor, PhD, MD, the main scientistic researcher
Әдебиет тізімі
- Прилепская В.Н., ред. Руководство по контрацепции. М.: МЕДпресс-информ; 2010. [Prilepskaya V.N., ed. Contraceptive guide. Мoscow: MEDpress-inform; 2010. (in Rusian)]
- Charlton B.M., Molgaard-Nielsen D., Svanström H., Wohlfahrt J., Pasternak B., Melbye M. Maternal use of oral contraceptives and risk of birth defects in Denmark: prospective, nationwide cohort study. BMJ. 2016; 352: h6712. doi: 10.1136/bmj.h6712.
- Benson L.S., Micks E.A. Why Stop Now? Extended and continuous regimens of combined hormonal contraceptive methods. Obstet. Gynecol. Clin. North Am. 2015; 42(4): 669-81.
- Baldwin M.K., Jensen J.T. Contraception during the perimenopause. Maturitas. 2013; 76(3): 235-42. doi: 10.1016/j.maturitas.2013.07.009.
- Pazol K., Creanga A.A., Zane S.B., Burley K.D., Jamieson D.J.; Centers for Disease Control and Prevention (CDC). Abortion surveillance--United States, 2009. Morb. Mortal. Wkly Rep. Surveill. Summ. 2012; 61(8): 1-44.
- Faculty of Sexual & Reproductive Healthcare. Clinical guidance: contraception for women over 40 years. 2010. Available at: www.fsrh.org/pdfs/ ContraceptionOver40July10.pdf
- Lopez L.M., Grimes D.A., Schulz K.F., Curtis K.M. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst. Rev. 2014; (4): CD006133.
- Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., Schulz K.F. 20 pg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst. Rev. 2013; (8): CD003989. doi: 10.1002/14651858.CD003989.pub5.
- Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant metaanalysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015; 16(9): 1061-70. doi: 10.1016/S1470-2045(15)00212-0.
- Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2009). 2009. Available at: http://www.fsrh.org/ admin/uploads/UKMEC2009.pdf Accessed 14 May 2010.
- Vessey М., Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception. 2013; 88(6): 678-83. doi: 10.1016/j.contraception.2013.08.008.
- Curtis K.M., Tepper N.K., Jamieson D.J., Marchbanks P.A. Adaptation of the World Health Organization’s selected practice recommendations for contraceptive use for the United States. Contraception. 2013; 87(5): 513-6. doi: 10.1016/j. contraception.2012.08.024.
- Подзолкова Н.М., Роговская С.И., Колода Ю.А. Современная контрацепция. Новые возможности и критерии безопасности. М.: ГЭОТАР-Медиа; 2013. [Podzolkova N.M., Rogovskaya S.I., Koloda Yu.A. Modern contraception. New opportunities and safety criteria. Moscow: GEOTAR-Media; 2013. (in Russian)]
- Speroff L., Darney P.D. A clinical guide for contraception. 5th ed. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins; 2011.
- Hannaford P.C., Iversen L., Macfarlane T.V., Elliott A.M., Angus V., Lee A.J. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010; 340: c927. doi: 10.1136/bmj.c927.
- Прилепская В.Н. Гормональная контрацепция. Клинические лекции. М.: ГЭОТАР-Медиа; 2014. [Prilepskaya V.N. Hormonal contraception. Clinical lectures. Moscow: GEOTAR-Media; 2014. (in Russian)]
- Dinger J., Bardenheuer K., Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; 89(4): 253-63. doi: 10.1016/j.contraception.2014.01.023.
- Severinsen M.T., Kristensen S.R., Overvad K., Dethlefsen C., Tjonneland A., Johnsen S.P. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J. Clin. Epidemiol. 2010; 63(2): 223-8. doi: 10.1016/j.jclinepi.2009.03.018.
- Fritz M.A., Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health, Lippincott Williams &Wilkins; 2011.
- Reape K.Z., DiLiberti C.E., Hendy C.H., Volpe E.J. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception. 2008; 77(1): 34-9.
Қосымша файлдар
